Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 7.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 457,165 shares of the company's stock after acquiring an additional 33,200 shares during the period. Geode Capital Management LLC owned about 0.74% of Pulse Biosciences worth $8,020,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Quest Partners LLC purchased a new position in shares of Pulse Biosciences during the 2nd quarter worth about $91,000. Creative Planning raised its stake in Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company's stock worth $384,000 after purchasing an additional 11,667 shares during the period. Rhumbline Advisers boosted its holdings in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after purchasing an additional 1,608 shares during the last quarter. Barclays PLC boosted its holdings in shares of Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Pulse Biosciences during the 3rd quarter valued at $588,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Stock Performance

Shares of NASDAQ PLSE traded up $1.84 during midday trading on Friday, hitting $19.63. The stock had a trading volume of 136,204 shares, compared to its average volume of 132,252. Pulse Biosciences, Inc. has a 1-year low of $6.59 and a 1-year high of $22.69. The company has a fifty day moving average price of $18.06 and a 200 day moving average price of $16.95.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the business earned ($0.19) EPS.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research report on Thursday.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert W. Duggan acquired 55,256 shares of the stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of $17.18 per share, with a total value of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares of the company's stock, valued at $727,207,358.06. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company's stock.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.